PHIO

Phio Pharmaceuticals Corp

Apr 09 • 04:00PM ET

1.25

-0.05 -3.85 %

Healthcare • Biotechnology • USA • NASD

Peers: GTBP AEON DRMA BCLI BTAI SNGX ALZN QNRX REGN VRTX

Index	-	P/E	-	EPS (ttm)	-1.50	Insider Own	11.57%	Shs Outstand	11.62M	Perf Week	-3.85%
Market Cap	14.52M	Forward P/E	-	EPS next Y	-0.62	Insider Trans	1.51%	Shs Float	10.27M	Perf Month	1.63%
Enterprise Value	-6.51M	PEG	-	EPS next Q	-0.23	Inst Own	3.13%	Short Float	5.70%	Perf Quarter	3.31%
Income	-8.70M	P/S	-	EPS this Y	34.48%	Inst Trans	3.27%	Short Ratio	0.15	Perf Half Y	-46.81%
Sales	0.00M	P/B	0.72	EPS next Y	34.74%	ROA	-63.90%	Short Interest	0.59M	Perf YTD	19.05%
Book/sh	1.73	P/C	0.69	EPS next 5Y	-	ROE	-69.95%	52W High	4.19 -70.17%	Perf Year	-18.83%
Cash/sh	1.81	P/FCF	-	EPS past 3/5Y	74.81% 62.91%	ROIC	-43.17%	52W Low	0.81 53.81%	Perf 3Y	-97.57%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.45% 6.20%	Perf 5Y	-99.58%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	85.44%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	16.03	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	52.31	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	16.03	EPS Q/Q	78.24%	SMA20	0.60%	Beta	0.88	Target Price	14.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	7.54%	Rel Volume	0.02	Prev Close	1.30
Employees	6	LT Debt/Eq	0.00	Earnings	Mar 05 AMC	SMA200	-25.68%	Avg Volume	3.80M	Price	1.25
IPO	May 10, 2012	Option/Short	No / Yes	EPS/Sales Surpr.	55.88% -	Trades		Volume	59,905	Change	-3.85%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-25	Resumed	H.C. Wainwright	Buy	$14
Aug-05-20	Initiated	H.C. Wainwright	Buy	$4

Apr-09-26 07:00AM	Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 (Newsfile)
Mar-30-26 07:00AM	Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762 (Newsfile Corp.)
Mar-23-26 07:00AM	Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement (Newsfile)
Mar-16-26 11:30AM	Phio Pharmaceuticals Announces 'A Groundbreaking Approach to Treating Skin Cancer' in a Fireside Chat with Force Family Office (Newsfile) +7.69%
Mar-10-26 07:00AM	Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT (Newsfile)
04:05PM	Loading…
Mar-05-26 04:05PM	Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update (Newsfile)
07:00AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile)
Feb-23-26 09:45AM	Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company (NewMediaWire)
Feb-19-26 07:00AM	Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894 (Newsfile)
Feb-12-26 08:43AM	What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? (Benzinga) -5.43%
Feb-10-26 11:12AM	Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients (Benzinga) +24.44%
07:00AM	Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial (Newsfile)
Jan-26-26 08:15AM	Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference (Newsfile)
Jan-20-26 09:30AM	Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial (Newsfile) -5.26%
Jan-15-26 08:45AM	Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026 (Newsfile)
08:45AM	Loading…
Dec-23-25 08:45AM	Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 (Newsfile) -6.36%
Nov-25-25 11:30AM	Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 (Newsfile)
Nov-17-25 08:45AM	Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress (Newsfile)
Nov-13-25 04:15PM	Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (Newsfile) -9.49% -9.09%
Nov-07-25 10:30AM	Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762 (Newsfile) +5.41%
07:45AM	Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program (Newsfile)
Nov-03-25 01:40PM	Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds (Newsfile) -9.27%
07:45AM	Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial (Newsfile)
Oct-31-25 10:15AM	Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director (Newsfile)
Oct-21-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile)
Sep-23-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile)
Sep-18-25 07:45AM	Phio Pharmaceuticals to Present at the Life Sciences Future Conference (Newsfile)
Sep-03-25 07:45AM	Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Newsfile)
Aug-14-25 04:15PM	Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (Newsfile)
Jul-25-25 03:04PM	Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds (Newsfile) +9.16%
12:36PM	Loading…
12:36PM	Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort (Newsfile)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:45AM	Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance (Newsfile)
Jun-25-25 07:45AM	Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort (Newsfile)
Jun-24-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Jun-06-25 07:45AM	Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio (Newsfile) +20.33%
May-28-25 09:02AM	Best Value Stocks to Buy for May 28th (Zacks) +16.96%
04:37AM	New Strong Buy Stocks for May 28th (Zacks)
May-20-25 08:00AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
May-19-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference (Newsfile)
May-15-25 04:15PM	Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (Newsfile)
May-07-25 07:45AM	Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial (Newsfile) +18.60%
May-01-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Apr-23-25 10:15AM	Best Momentum Stocks to Buy for April 23rd (Zacks) -18.73%
06:45AM	Best Value Stocks to Buy for April 23rd (Zacks)
Apr-10-25 10:53AM	PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose (Zacks) +7.14%
Apr-09-25 07:45AM	Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort (Newsfile) +52.48%
Apr-03-25 07:45AM	Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894 (Newsfile)
Mar-31-25 04:00PM	Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update (Newsfile) -5.38%
Mar-10-25 07:45AM	American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting (Newsfile)
Mar-05-25 07:45AM	Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study (Newsfile) +5.30%
Feb-26-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Feb-20-25 07:45AM	Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors (Newsfile)
Feb-03-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Jan-22-25 07:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) -7.66%
Jan-21-25 11:15AM	Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -10.47%
Jan-16-25 01:00PM	Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) +9.40%
Jan-15-25 07:00AM	Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -25.70%
Jan-14-25 07:00AM	Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -45.76%
Jan-13-25 12:45PM	Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why (Benzinga) +290.53%
07:45AM	Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762 (Newsfile)
Jan-02-25 07:45AM	Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology (Newsfile) +5.56%
Dec-23-24 01:15PM	Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) +26.70%
Dec-19-24 02:28PM	Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -30.68%
07:45AM	Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762 (Newsfile)
Dec-12-24 09:21AM	Phio Pharmaceuticals Announces Publication in Frontiers in Immunology (Newsfile) +6.34%
Dec-10-24 07:45AM	Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award (Newsfile)
Dec-03-24 07:45AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Nov-19-24 07:45AM	Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study (Newsfile) +12.42%
Nov-14-24 05:47PM	Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (Newsfile) -5.11%
Nov-07-24 10:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Newsfile)
Nov-01-24 07:45AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Oct-24-24 08:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Newsfile)
Oct-18-24 01:30PM	Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) +9.81%
08:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series (Newsfile)
Oct-16-24 08:00AM	Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference (Newsfile) +17.75%
Oct-07-24 08:00AM	Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells (Newsfile) -6.17%
Oct-02-24 04:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) -6.47%
Oct-01-24 08:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference (Newsfile)
Sep-25-24 08:00AM	INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society (Newsfile)
Sep-17-24 08:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) +11.64%
Sep-16-24 08:00AM	Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA (Newsfile)
Sep-09-24 07:00AM	Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Newsfile) +6.13%
Aug-29-24 08:30AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) -7.37%
Aug-14-24 05:00PM	Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (Newsfile)
Aug-06-24 08:00AM	Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound (Newsfile)
Aug-01-24 08:00AM	Phio Pharmaceuticals Announces New Chief Financial Officer (Newsfile) -7.34%
Jul-12-24 08:00AM	Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds (Newsfile) -13.60%
Jul-08-24 08:00AM	Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762 (Newsfile) +9.06%
Jul-05-24 08:00AM	Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds (Newsfile)
Jul-02-24 11:45AM	Phio Pharmaceuticals Announces Reverse Stock Split (Newsfile) -9.17%
Jun-18-24 07:30AM	Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging (Newsfile)
May-28-24 07:30AM	Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762 (Newsfile)
May-23-24 05:00PM	Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (Newsfile)
May-17-24 09:00AM	Phio Pharmaceuticals Secures New Investor (GlobeNewswire) +7.44%
May-16-24 08:00AM	Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID) (GlobeNewswire) -8.45%
May-15-24 01:00PM	Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study (GlobeNewswire) +9.02%
May-09-24 11:53PM	PHIO Stock Earnings: Phio Pharma Reported Results for Q1 2024 (InvestorPlace) -8.51%
05:25PM	Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update (GlobeNewswire)
Apr-30-24 07:30AM	Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO) (GlobeNewswire)

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bitterman Robert J	Chairman, Pres. & CEO	Dec 31 '25	Buy	1.03	5,000	5,150	291,421	Jan 02 04:05 PM
Bitterman Robert J	Chairman, Pres. & CEO	Dec 23 '25	Buy	1.02	5,000	5,100	286,421	Dec 29 08:10 AM
Bitterman Robert J	Chairman, Pres. & CEO	Nov 21 '25	Buy	1.14	5,000	5,700	281,421	Nov 24 12:54 PM
Bitterman Robert J	Chairman, Pres. & CEO	Nov 18 '25	Buy	1.27	5,000	6,350	276,421	Nov 19 12:47 PM
Bitterman Robert J	Chairman, Pres & CEO	Jun 10 '25	Buy	2.42	2,000	4,840	27,149	Jun 11 05:00 PM
Ferrara Robert L	Director	Jun 10 '25	Buy	2.42	2,500	6,050	15,666	Jun 11 04:59 PM
Bitterman Robert J	Chairman, Pres & CEO	Jun 09 '25	Buy	2.75	1,500	4,125	25,149	Jun 10 04:43 PM
Bitterman Robert J	Chairman, Pres & CEO	May 21 '25	Buy	1.77	3,000	5,310	22,449	May 23 09:04 AM
Bitterman Robert J	Chairman, Pres & CEO	May 22 '25	Buy	1.78	1,200	2,136	23,649	May 23 09:04 AM
Ferrara Robert L	Director	May 20 '25	Buy	1.82	2,500	4,550	13,166	May 21 04:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHIO

Phio Pharmaceuticals Corp

Upgrade your Finviz experience